Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.